Pacira BioSciences, Inc. (PCRX)

Working capital turnover

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Revenue US$ in thousands 700,966 674,978 666,823 541,533 420,830
Total current assets US$ in thousands 745,130 509,994 498,334 866,048 651,623
Total current liabilities US$ in thousands 309,920 97,383 147,774 521,118 253,328
Working capital turnover 1.61 1.64 1.90 1.57 1.06

December 31, 2024 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $700,966K ÷ ($745,130K – $309,920K)
= 1.61

The working capital turnover ratio for Pacira BioSciences, Inc. has shown a generally increasing trend over the past five years, from 1.06 in December 31, 2020, to 1.61 in December 31, 2024. This indicates that the company's efficiency in utilizing its working capital to generate sales has improved over the period. The peak value of 1.90 at December 31, 2022 suggests a significant enhancement in the company's ability to convert its working capital into revenue during that year. Overall, the rising trend in the working capital turnover ratio reflects positively on Pacira BioSciences' management of working capital resources to support its business operations.